Nectar Lifesciences Limited

BSE: NECLIFE532649ISIN INE023H01027

Healthcare
Pharmaceuticals

Share price

₹10.32+0.07 (+0.68%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹22.49
52W low: ₹9.20
Off 52W high: -54.11%
1M return: -2.37%
3M return: -2.27%
6M return: -16.50%
1Y return: -27.12%
20D avg volume: 25,123
50 DMA: ₹11.05
200 DMA: ₹11.74

Key ratios Consolidated

Market cap: ₹200.48 Cr
Current price: ₹10.32
52W high / low: ₹22.49 / ₹9.20
Face value: ₹1.00
P/E: -0.82
P/B: 0.34
EPS (TTM): ₹-12.61
Book value / share: ₹29.97
ROE: —
ROCE: -8.70%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹0.00 Cr
Interest cover: -1.43
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 130.4 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	0.01	0.00	0.00	5.00	280.67	430.69	454.98	428.10	359.30	—
	3.35	7.58	0.66	0.74	0.35	0.08	0.57	0.69	0.55	—
	3.36	7.58	0.66	5.74	281.02	430.77	455.56	428.79	359.85	—
	27.98	64.51	32.21	6.24	377.78	618.44	443.01	420.12	354.93	—
	0.00	0.00	0.00	3.41	236.07	405.70	294.15	253.89	296.98	—
	0.03	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	1.06	1.26	0.61	0.75	24.26	23.81	24.50	24.18	23.99	—
	0.16	5.90	30.23	0.00	18.70	17.67	17.12	19.81	19.98	—
	0.11	0.08	0.06	0.20	16.52	15.77	15.61	15.55	15.46	—
	26.64	57.26	1.32	1.93	54.76	58.61	53.73	64.54	58.17	—
	-24.62	-56.93	-31.55	-0.51	-96.75	-187.66	12.55	8.67	4.92	—
	0.00	0.00	88.15	0.00	0.00	0.00	0.00	0.00	0.00	—
	-24.62	-56.93	56.60	-0.51	-96.75	-187.66	12.55	8.67	4.92	—
	-8.90	-19.72	11.03	-0.18	33.52	-57.58	4.71	3.07	1.95	—
	-15.40	-67.92	14.27	-176.01	-63.23	-130.09	7.84	5.60	2.97	—
	-0.81	-3.38	3.02	-7.84	-2.82	-5.80	0.35	0.25	0.13	—
Key metrics
	-24.35	-50.95	86.89	-0.31	-61.53	-154.22	45.28	44.03	40.36	—
	-2,43,500.00%	—	—	-6.20%	-21.90%	-35.80%	10.00%	10.30%	11.20%	—
	-1,54,000.00%	—	—	-3,520.20%	-22.50%	-30.20%	1.70%	1.30%	0.80%	—
	—	-8.60%	—	0.00%	—	-16.60%	—	—	—	—
	-100.00%	-100.00%	-100.00%	-98.80%	-21.90%	—	—	—	—	—
	75.60%	47.80%	82.00%	-3,243.00%	-2,229.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	5.01	0.00	1,673	—
	12.33	9.29	1.89	—
	17.34	9.29	1,675	—
	130.94	97.17	1,836	—
	3.41	0.00	1,251	—
	0.03	0.00	0.00	—
	3.68	1.91	96.47	—
	36.29	36.13	74.58	—
	0.45	0.34	62.39	—
	87.15	58.79	235.05	—
	-113.61	-87.88	-161.53	—
	88.15	0.00	0.00	—
	-25.46	-87.88	-161.53	—
	-17.77	30.53	47.85	—
	-245.06	-292.89	-113.68	—
	-9.01	-13.40	-5.07	—
Key metrics
	11.28	-51.41	-24.56	—
	225.15%	—	-1.50%	—
	-4,891.42%	—	-6.80%	—
	—	-8.70%	-8.50%	—
	-99.69%	-100.00%	—	—
	—	-157.60%	—	—
	—	-360.99	125.65	—
	—	1.19	-1.49	—
	—	0.00	0.61	—
	—	0.00	562.81	—
	—	—	130.4	—
Balance sheet
	—	621.61	2,047	—
	—	252.97	1,238	—
	—	0.00	19.22	—
	—	0.00	345.48	—
	—	0.30	690.16	—
	—	61.47	173.82	—
	—	103.40	576.60	—
	—	0.00	438.12	—
	—	26.05	1,022	—
	—	0.00	582.03	—
	—	0.00	521.90	—
	—	0.00	60.13	—
	—	582.30	956.11	—
Cash flow
	—	-348.72	169.44	—
	—	1,208	-41.93	—
	—	-766.51	-128.09	—
	—	12.27	43.79	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	0.01	0.00	0.00	5.00	280.67	430.69	454.98	428.10	359.30	—
	6.28	7.58	0.66	0.74	0.35	0.08	0.57	0.69	0.55	—
	6.29	7.58	0.66	5.74	281.02	430.77	455.56	428.79	359.85	—
	27.95	64.50	32.21	6.24	377.78	618.44	443.01	420.12	354.93	—
	0.00	0.00	0.00	3.41	236.07	405.70	294.15	253.89	296.98	—
	0.03	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	1.03	1.25	0.61	0.75	24.26	23.81	24.50	24.18	23.99	—
	0.16	5.90	30.22	0.00	18.70	17.67	17.12	19.81	19.98	—
	0.11	0.08	0.06	0.20	16.52	15.77	15.61	15.55	15.46	—
	26.64	57.26	1.32	1.93	54.76	58.61	53.73	64.54	58.17	—
	-21.66	-56.92	-31.55	-0.51	-96.75	-187.66	12.55	8.67	4.92	—
	0.00	0.00	88.15	0.00	0.00	0.00	—	—	—	—
	-21.66	-56.92	56.60	-0.51	-96.75	-187.66	12.55	8.67	4.92	—
	8.20	-19.71	11.03	0.18	-33.52	-57.58	4.71	3.07	1.95	—
	-13.14	-67.92	14.27	-176.01	-63.23	-130.09	7.84	5.60	2.97	—
	-0.69	-3.38	3.02	-7.84	-2.82	-5.80	0.35	0.25	0.13	—
Key metrics
	-21.39	-50.94	86.88	-0.31	-61.53	-154.22	45.28	44.03	40.36	—
	-2,13,900.00%	—	—	-6.20%	-21.90%	-35.80%	10.00%	10.30%	11.20%	—
	-1,31,400.00%	—	—	-3,520.20%	-22.50%	-30.20%	1.70%	1.30%	0.80%	—
	—	-8.70%	—	0.00%	—	-16.60%	—	—	—	—
	-100.00%	-100.00%	-100.00%	-98.80%	-21.90%	—	—	—	—	—
	79.20%	47.80%	82.00%	-3,243.00%	-2,229.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	5.01	0.00	1,673	—
	15.26	9.29	1.89	—
	20.27	9.29	1,675	—
	130.90	97.16	1,836	—
	3.41	0.00	1,251	—
	0.03	0.00	0.00	—
	3.64	1.90	96.47	—
	36.28	36.13	74.58	—
	0.45	0.34	62.39	—
	87.15	58.79	235.05	—
	-110.64	-87.87	-161.53	—
	88.15	0.00	0.00	—
	-22.49	-87.87	-161.53	—
	-0.30	30.53	-47.85	—
	-242.80	-292.88	-113.68	—
	-8.89	-13.40	-5.07	—
Key metrics
	14.24	-51.40	-24.56	—
	284.23%	—	-1.50%	—
	-4,846.31%	—	-6.80%	—
	—	-8.80%	-8.50%	—
	-99.69%	-100.00%	—	—
	—	-157.60%	—	—
	—	-428.88	125.65	—
	—	1.42	-1.49	—
	—	0.00	0.61	—
	—	0.00	562.81	—
	—	—	130.4	—
Balance sheet
	—	612.34	2,047	—
	—	249.57	1,238	—
	—	0.00	19.22	—
	—	0.00	345.48	—
	—	0.30	690.16	—
	—	62.08	173.82	—
	—	3.45	576.60	—
	—	0.00	438.12	—
	—	25.97	1,022	—
	—	0.00	582.03	—
	—	0.00	521.90	—
	—	0.00	60.13	—
	—	582.31	956.11	—
Cash flow
	—	-417.35	169.44	—
	—	1,205	-41.93	—
	—	-699.15	-128.09	—
	—	11.53	43.79	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -99.69%
Profit YoY (TTM): -34.98%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -99.69%
Profit YoY (TTM): -36.24%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 51.85%

Quarter	September 2026	June 2026
Promoter %	51.85%	51.85%

Holder	Type	Holding	Previous	Change
SANJIV GOYAL	Promoter	24.63%	24.63%	0.00%
SANJIV (HUF) - KARTA SANJIV GOYAL	Promoter	22.46%	22.46%	0.00%
RAMAN GOYAL	Promoter Group	4.76%	4.76%	0.00%
RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED	Public	3.90%	3.73%	+0.17%
ORIENT ALLOYS PRIVATE LIMITED	Promoter Group	0.00%	0.00%	0.00%
NECTAR ORGANICS PRIVATE LIMITED	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Nectar Lifesciences Limited	200	10.32	-0.82	-8.70%	-99.69% TTM	-36.24% TTM	-27.12%

Filings & corporate actions

Recent announcements

Please find attached herewith certificate as per caption regulations6 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached herewith copy of minutes of 31st AGM of the Company.5 Oct 2026 · AGM/EGM / AGM
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 20153 Oct 2026 · Company Update / General
Trading window closure pursuant to SEBI ( Prohibition of Insider Trading) Regulations, 201524 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please find attached herewith Revised Proceedings of 31st AGM19 Sep 2026 · Company Update / General
Please find attached herewith outcome of Annual General Meeting held on September 18, 2026 with a copy Scrutinizer report and voting results.18 Sep 2026 · AGM/EGM / AGM
Please find attached herewith Proceedings of 31st AGM18 Sep 2026 · AGM/EGM / AGM
Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.22 Aug 2026 · Company Update / General
Please find attached herewith newspaper publication of notice of 31st Annual General Meeting, e-voting, book closure & other information.21 Aug 2026 · Company Update / Newspaper Publication
Pursuant to Regulations 30 and 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of Annual ....20 Aug 2026 · Others / Reg. 34 (1) Annual Report
Please find attached herewith Notice of 31st AGM for the Financial Year 2025-26 is scheduled to be held on Friday, September 18, 202620 Aug 2026 · AGM/EGM / AGM
Please find attached herewith newspaper publication of notice to the shareholders regarding 31st AGM of the Company to be held on Friday, September 18, 2026, through Video Conferencing ....20 Aug 2026 · Company Update / Newspaper Publication
Please find attached herewith copies of newspaper publication of financial results ended on June 30, 2026.15 Aug 2026 · Company Update / Newspaper Publication
Please find attached herewith letter of change in corporate office of the Company15 Aug 2026 · Company Update / Change in Corporate Office Address
AGM to be held on September 18, 2026 and book closure date for the same is from September 12, 2026 to September 18, 2026(both days inclusive). The Cut-off date, to ascertain the eligibility ....14 Aug 2026 · Corp. Action / Book Closure
We wish to inform you that the board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the ....14 Aug 2026 · Board Meeting / Outcome of Board Meeting
Please find attached herewith the financial results for the quarter ended on June 30, 2026.14 Aug 2026 · Result / Financial Results
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....10 Aug 2026 · Board Meeting / Board Meeting
Please find attached herewith letter of Resignation of Non-Executive Non-Independent Director of the Nectar Lifesciences Limited6 Aug 2026 · Company Update / Resignation of Director
Please find attached herewith letter of Sale and Surrender of Leasehold Rights in Land Situated in Jammu4 Aug 2026 · Company Update / General
Please find attached herewith letter w.r.t.: Update on Slump Sale23 Jul 2026 · Company Update / General
We wish to inform you that the board of directors of Nectar Lifesciences Limited (''Company'') has change the registered office of the Company11 Jul 2026 · Company Update / Change in Registered Office Address
Please find attached herewith the certificate as per caption regulations4 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201524 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please find attached herewith copy of newspaper publication as per Section 124(6) of Companies Act, 201316 Jun 2026 · Company Update / Newspaper Publication
Please find attached herewith the copy of newspapers for publication of financial results of the Company for the quarter and financial year ended on March 31, 20261 Jun 2026 · Company Update / Newspaper Publication
Financial Results for the Year 2025-2630 May 2026 · Result / Financial Results
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....25 May 2026 · Board Meeting / Board Meeting
Please find attached herewith letter w.r.t.: Update on Slump Sale28 Apr 2026 · Company Update / General
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 201528 Apr 2026 · Company Update / General
Please find attached herewith Annual Secretarial Compliance Report for the year ended on March 31, 202618 Apr 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Please find attachment.8 Apr 2026 · Company Update / General
Please find attached herewith the certificate as per captioned regulations6 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201525 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 201524 Mar 2026 · Company Update / General
Please find attached herewith the Minutes of the Ordinary and Special Resolutions passed by way of Postal Ballot by the Members of the Company as set out in the Postal Ballot Notice dated ....13 Mar 2026 · AGM/EGM / Postal Ballot
Please find attached herewith Intimation of inter-corporate loan agreement with Avensis Exports Private Limited, a Wholly Owned Subsidiary of the Nectar Lifesciences Limited12 Mar 2026 · Company Update / General
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 20157 Mar 2026 · Company Update / General
Update on Acquisition of 100% paid- up equity share capital of Avensis Exports Private Limited (CIN: U51109DL2007PTC169484)6 Mar 2026 · Company Update / Acquisition
Updation of disclosures by Nectar Lifesciences Limited as per point no. 1 of its letter no. NLL/CS/2026- 659 dated March 02, 2026.3 Mar 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Buy Back of Shares	24 Dec 2025	24 Dec 2025	—

Board meetings

14 Aug 2026 Board Meeting - Financial Results